Advisor Group’s Akari Therapeutics AKTX Stock Holding History

Advisor Group’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$2K	Buy	+1	New	+$1.47K	﹤0.01%	4947
2019 Q2	–	Hold	0	–	–	–	5207
2019 Q1	–	Hold	0	–	–	–	5191
2018 Q4	–	Hold	0	–	–	–	5083
2018 Q3	–	Hold	0	–	–	–	5085
2018 Q2	–	Hold	0	–	–	–	4910
2018 Q1	–	Hold	0	–	–	–	4933
2017 Q4	–	Hold	0	–	–	–	4938
2017 Q3	–	Sell	-8	Closed	-$30K	–	4819
2017 Q2	$29K	Buy	+8	New	+$63.3K	﹤0.01%	3227
2017 Q1	–	Hold	0	–	–	–	4670
2016 Q4	–	Hold	0	–	–	–	4487
2016 Q3	–	Hold	0	–	–	–	4457
2016 Q2	–	Hold	0	–	–	–	4383

Other funds holding AKTX

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OFW

Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisor Group's AKTX Position: Q4 2019 in Review

Advisor Group opened a new position in Akari Therapeutics (AKTX) in Q4 2019: 1 share worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #4947 among its holdings. This is a return to the name: Advisor Group previously reported a position in AKTX as recently as Q2 2017.

Advisor Group first reported a position in AKTX in Q2 2017 and has held it in 2 quarters since. The position peaked at $29K in Q2 2017. 13 funds tracked by Wall St. Rank hold AKTX as of Q4 2019.

Advisor Group held 1 share of Akari Therapeutics worth $2K as of Q4 2019.
Akari Therapeutics was a new Advisor Group position in Q4 2019.
Akari Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4947 holding.
Advisor Group first reported a position in Akari Therapeutics in Q2 2017 and has held it in 2 quarters since.
Advisor Group's Akari Therapeutics position peaked at $29K in Q2 2017.
13 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.